Oncolytics Biotech (ONCY) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed Oncolytics Biotech (ONCY) over the past year, gaining 9.6% versus a loss of 57.5%. Over five years, ONCY leads with a -75.5% price change compared with -95.1% for RFL. Rafael is the larger company by market cap ($77.0 million vs $71.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCY | RFL |
|---|---|---|
| Share price | $0.5444 | $1.48 |
| Market cap | $71.38M | $76.96M |
| 1-day change | -8.63% | 0.00% |
| YTD return | -37.43% | +25.42% |
| 1-year return | -57.47% | +9.63% |
| 5-year return | -75.48% | -95.09% |
| EPS (TTM) | $-0.35 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.32 | $3.96 |
| 52-week low | $0.54 | $1.12 |
| Distance from 52-week high | -58.76% | -62.63% |
| Analyst consensus | buy | — |
| Avg. price target upside | +662.31% | — |
| Average volume | 1.08M | 159.84K |
| Shares outstanding | 131.12M | 51.21M |
| Employees | 29 | 21 |
| Sector | Healthcare | Real Estate |
| Industry | Biotechnology | Real Estate Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed ONCY by 67.1 percentage points over the past year.
- The two companies sit in different sectors: Oncolytics Biotech in Healthcare and Rafael in Real Estate.
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Healthcare · Biotechnology · 29 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Real Estate · Real Estate Services · 21 employees
ONCY vs RFL FAQ
Which is bigger, Oncolytics Biotech or Rafael?
Rafael (RFL) is larger, with a market capitalization of $76.96M compared with $71.38M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, ONCY or RFL?
RFL returned +9.63% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Oncolytics Biotech and Rafael in the same industry?
No. Oncolytics Biotech is in the Healthcare sector, while Rafael is in Real Estate.